Literature DB >> 18254782

Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia.

Meliha Meric1, Ayse Willke, Enrst-Jurgen Finke, Roland Grunow, Murat Sayan, Sarper Erdogan, Suna Gedikoglu.   

Abstract

Tularemia outbreaks have occurred in various regions of Turkey in recent years. In this study, clinical (145 patients) and laboratory (97 patients) features of patients with oropharyngeal tularemia were evaluated during the tularemia outbreak in the district of Gölcük in Kocaeli, Turkey. We analyzed the risk factors for therapeutic failure and prolonged recovery time, and compared the efficacy of three antibiotic groups, namely aminoglycoside, tetracycline and quinolone. The most common physical sign and laboratory findings in patients were lymphadenopathy (LAP) and increased erythrocyte sedimentation rate, respectively. Treatment failure was observed in 55 of the 145 (38%) patients during one-year follow-up and the most successful results were obtained in the quinolone group. It was determined that antimicrobial therapy initiated 14 days after onset of symptoms was a statistically significiant risk factor, reducing the success rate (p=0.0001, OR=13.10, 95% CI=5.69-30.15) and prolonging the recovery period (p=0.001, OR=3.23, 95% CI=1.63-6.40) in oropharyngeal tularemia cases. These results suggest that antimicrobial treatment should be started early, and quinolones such as moxifloxacin and ciprofloxacin seem to be new alternatives in the treatment of oropharyngeal tularemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254782     DOI: 10.1111/j.1600-0463.2008.00901.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  18 in total

1.  Characteristics and management of intractable neck involvement in tularemia: report of 19 patients.

Authors:  Yusuf Kızıl; Utku Aydil; Süleyman Cebeci; Osman Tuğrul Güzeldir; Erdoğan Inal; Yıldırım Bayazıt
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-09       Impact factor: 2.503

2.  Ciprofloxacin: Tularemia (Adults).

Authors:  Joyce A Generali; Dennis J Cada
Journal:  Hosp Pharm       Date:  2015-04-08

Review 3.  Tularemia: a rare cause of neck mass, evaluation of 33 patients.

Authors:  Sedat Cağlı; Alperen Vural; Onur Sönmez; Imdat Yüce; Ercihan Güney
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-08-04       Impact factor: 2.503

4.  Suppurative lymphadenitis.

Authors:  Iain P Fraser
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

5.  Glycan targeted polymeric antibiotic prodrugs for alveolar macrophage infections.

Authors:  Jasmin Chen; Fang-Yi Su; Debobrato Das; Selvi Srinivasan; Hye-Nam Son; Brian Lee; Frank Radella; Dale Whittington; Taylor Monroe-Jones; T Eoin West; Anthony J Convertine; Shawn J Skerrett; Patrick S Stayton; Daniel M Ratner
Journal:  Biomaterials       Date:  2018-10-16       Impact factor: 12.479

6.  Water-borne outbreak of oropharyngeal and glandular tularemia in Georgia: investigation and follow-up.

Authors:  N Chitadze; T Kuchuloria; D V Clark; E Tsertsvadze; M Chokheli; N Tsertsvadze; N Trapaidze; A Lane; L Bakanidze; S Tsanava; M J Hepburn; P Imnadze
Journal:  Infection       Date:  2009-10-13       Impact factor: 3.553

7.  Tularemia in central Anatolia.

Authors:  A Ulu-Kilic; G Gulen; F Sezen; S Kilic; I Sencan
Journal:  Infection       Date:  2012-10-27       Impact factor: 3.553

8.  The devil is in the details.

Authors:  Ian Jenkins; Joseph Vinetz
Journal:  J Hosp Med       Date:  2009-07       Impact factor: 2.960

Review 9.  Epidemiology of tularemia.

Authors:  Saban Gürcan
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

10.  Performance of seven serological assays for diagnosing tularemia.

Authors:  Valérie Chaignat; Marina Djordjevic-Spasic; Anke Ruettger; Peter Otto; Diana Klimpel; Wolfgang Müller; Konrad Sachse; George Araj; Roland Diller; Herbert Tomaso
Journal:  BMC Infect Dis       Date:  2014-05-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.